Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer

Descripción del Articulo

Background: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru
Detalles Bibliográficos
Autores: Serrano, M, Araujo, JM, Pacheco-Román, C, Macetas, J, Blum, MA, Carrato, A, Ruiz-Figueroa, E, Berrospi-Espinoza, F, Luque Vasquez, C, Chavez-Pasiuri, IK, Payet-Meza, ET, Taxa-Rojas, L, Montenegro, P
Formato: artículo
Fecha de Publicación:2022
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/274
Enlace del recurso:https://hdl.handle.net/20.500.14703/274
Nivel de acceso:acceso abierto
Materia:adjuvant chemotherapy
gastric cancer
survival
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_b3b37c5ea6b155316db65d8cccd9d384
oai_identifier_str oai:repositorio.inen.sld.pe:20.500.14703/274
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
spelling PublicationSerrano, MAraujo, JMPacheco-Román, CMacetas, JBlum, MACarrato, ARuiz-Figueroa, EBerrospi-Espinoza, FLuque Vasquez, CChavez-Pasiuri, IKPayet-Meza, ETTaxa-Rojas, LMontenegro, P2025-01-02T14:42:06Z2025-01-02T14:42:06Z202210.3332/ecancer.2022.1387https://hdl.handle.net/20.500.14703/274ecancermedicalscienceBackground: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peruhowever, there are no prospective trials for adjuvant chemotherapy in GC after curative gastrectomy in this country. The objective of this study was to evaluate the effectiveness of adjuvant chemotherapy in stage II-III gastric cancer patients who underwent D2 gastrectomy. Methods: We included patients with stage II-III gastric cancer who underwent radical gastrectomy and D2 dissection between 2014 and 2016 at our institution. Patients received 3-week cycles of capecitabine (1,000 mg/m2 twice daily on days 1-14) plus oxaliplatin (130 mg/m2 on day 1) for 6 months. Survival curves were estimated with the Kaplan-Meier method, and the Cox proportional hazards model was used to identify prognostic factors for survival. Results: In total, 173 patients were included: 100 (57.8%) patients received adjuvant chemotherapy and surgery (AChS) and 73 (42.2%) surgery alone (SA). Three-year diseasefree survival (DFS) was higher in the AChS groups (69%) than in the SA group (52.6%) (p = 0.034). Regarding overall survival (OS), 31 patients (31%) died in the AChS group compared with 34 (46.6%) in the SA group (p = 0.027). In the multivariate analysis, adjuvant chemotherapy was an independent prognostic factor for DFS (HR = 0.6095% CI = 0.37-0.97p = 0.036) and OS (HR = 0.5895% CI = 0.36-0.95p = 0.029). ACh showed consistent benefit in DFS and OS for patients with albumin >3.5 g/dL, lymphovascular and perineural invasion, pT4, pN2-3, pathologic stage (PS) IIIA and IIIB and lymph node ratio (LNR) > 13.1. Conclusion: These data suggest that adjuvant capecitabine and oxaliplatin reduce the recurrence and mortality in patients with stage II-III gastric cancer who underwent D2 gastrectomy. PS IIIA and IIIB and LNR > 13.1 benefited more from receiving adjuvant chemotherapy and poorly cohesive gastric carcinoma did not significantly reduce the rates of survival. Copyright: © 2022 the authorslicensee ecancermedicalscience.application/pdfengecancer Global FoundationUKinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/adjuvant chemotherapygastric cancersurvivalhttps://purl.org/pe-repo/ocde/ford#3.02.21Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancerinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALSerrano; 2022 application/pdf877229https://repositorio.inen.sld.pe/backend/api/core/bitstreams/40e6a563-bbd6-41db-8fdd-9597c92d0c88/download7889ab5d3ad249987c2c757c7813beafMD51trueAnonymousREADTEXTSerrano; 2022 .txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-03-29T20:39:22Z (GMT).Extracted texttext/plain40451https://repositorio.inen.sld.pe/backend/api/core/bitstreams/9e00d5a1-6e0a-49b8-a5af-2d75c7e91ba1/downloaddce23640898faa54ba1b0ea99f220d5eMD54falseAnonymousREADTHUMBNAILSerrano; 2022 .jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-03-29T20:39:22Z (GMT).Generated Thumbnailimage/jpeg40203https://repositorio.inen.sld.pe/backend/api/core/bitstreams/8ef414c6-1efc-41d1-87d2-59705401d832/downloade486f3ea3f7c616b91baee12848363ddMD55falseAnonymousREAD20.500.14703/274oai:repositorio.inen.sld.pe:20.500.14703/2742026-02-15T18:44:17.062Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.pe
dc.title.none.fl_str_mv Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
title Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
spellingShingle Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
Serrano, M
adjuvant chemotherapy
gastric cancer
survival
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
title_full Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
title_fullStr Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
title_full_unstemmed Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
title_sort Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
author Serrano, M
author_facet Serrano, M
Araujo, JM
Pacheco-Román, C
Macetas, J
Blum, MA
Carrato, A
Ruiz-Figueroa, E
Berrospi-Espinoza, F
Luque Vasquez, C
Chavez-Pasiuri, IK
Payet-Meza, ET
Taxa-Rojas, L
Montenegro, P
author_role author
author2 Araujo, JM
Pacheco-Román, C
Macetas, J
Blum, MA
Carrato, A
Ruiz-Figueroa, E
Berrospi-Espinoza, F
Luque Vasquez, C
Chavez-Pasiuri, IK
Payet-Meza, ET
Taxa-Rojas, L
Montenegro, P
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Serrano, M
Araujo, JM
Pacheco-Román, C
Macetas, J
Blum, MA
Carrato, A
Ruiz-Figueroa, E
Berrospi-Espinoza, F
Luque Vasquez, C
Chavez-Pasiuri, IK
Payet-Meza, ET
Taxa-Rojas, L
Montenegro, P
dc.subject.none.fl_str_mv adjuvant chemotherapy
gastric cancer
survival
topic adjuvant chemotherapy
gastric cancer
survival
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Background: Gastric cancer (GC) is the fourth most common cause of cancer deaths around the world and the first cause of cancer deaths in Peru
publishDate 2022
dc.date.accessioned.none.fl_str_mv 2025-01-02T14:42:06Z
dc.date.available.none.fl_str_mv 2025-01-02T14:42:06Z
dc.date.issued.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv 10.3332/ecancer.2022.1387
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.14703/274
dc.identifier.journal.none.fl_str_mv ecancermedicalscience
identifier_str_mv 10.3332/ecancer.2022.1387
ecancermedicalscience
url https://hdl.handle.net/20.500.14703/274
dc.language.iso.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv ecancer Global Foundation
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv ecancer Global Foundation
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
bitstream.url.fl_str_mv https://repositorio.inen.sld.pe/backend/api/core/bitstreams/40e6a563-bbd6-41db-8fdd-9597c92d0c88/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/9e00d5a1-6e0a-49b8-a5af-2d75c7e91ba1/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/8ef414c6-1efc-41d1-87d2-59705401d832/download
bitstream.checksum.fl_str_mv 7889ab5d3ad249987c2c757c7813beaf
dce23640898faa54ba1b0ea99f220d5e
e486f3ea3f7c616b91baee12848363dd
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio del Instituto Nacional de Enfermedades Neoplásicas
repository.mail.fl_str_mv repositorio@inen.sld.pe
_version_ 1868438560417251328
score 12.824051
Adjuvant chemotherapy after curative D2 gastrectomy in Latin American patients with gastric cancer
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares